232 related articles for article (PubMed ID: 28777784)
1. The epigenome editors: How tools such as CRISPR offer new details about epigenetics.
Willyard C
Nat Med; 2017 Aug; 23(8):900-903. PubMed ID: 28777784
[No Abstract] [Full Text] [Related]
2. CRISPR/Cas-Based Epigenome Editing: Advances, Applications, and Clinical Utility.
Goell JH; Hilton IB
Trends Biotechnol; 2021 Jul; 39(7):678-691. PubMed ID: 33972106
[TBL] [Abstract][Full Text] [Related]
3. Epigenome editing to the rescue.
Elsner M
Nat Biotechnol; 2018 Apr; 36(4):315. PubMed ID: 29621214
[No Abstract] [Full Text] [Related]
4. Decoding the noncoding genome via large-scale CRISPR screens.
Shukla A; Huangfu D
Curr Opin Genet Dev; 2018 Oct; 52():70-76. PubMed ID: 29913329
[TBL] [Abstract][Full Text] [Related]
5. Genome and Epigenome Editing to Treat Disorders of the Hematopoietic System.
Mussolino C; Alzubi J; Pennucci V; Turchiano G; Cathomen T
Hum Gene Ther; 2017 Nov; 28(11):1105-1115. PubMed ID: 28806883
[TBL] [Abstract][Full Text] [Related]
6. Genome and Epigenome Editing in Mechanistic Studies of Human Aging and Aging-Related Disease.
Lau CH; Suh Y
Gerontology; 2017; 63(2):103-117. PubMed ID: 27974723
[TBL] [Abstract][Full Text] [Related]
7. Focus on CRISPR tools and therapies.
Nat Biotechnol; 2020 Jul; 38(7):765. PubMed ID: 32641851
[No Abstract] [Full Text] [Related]
8. The CRISPR/Cas9 Genome Editing Revolution.
Jiao R; Gao C
J Genet Genomics; 2016 May; 43(5):227-8. PubMed ID: 27256542
[No Abstract] [Full Text] [Related]
9. EPO revokes Broad's CRISPR patent.
Harrison C
Nat Biotechnol; 2018 Mar; 36(3):209. PubMed ID: 29509734
[No Abstract] [Full Text] [Related]
10. CRISPR target prediction remains blunt tool for clinical applications.
Hodgson J
Nat Biotechnol; 2019 Mar; 37(3):204-205. PubMed ID: 30833770
[No Abstract] [Full Text] [Related]
11. Plenary Symposia.
In Vitro Cell Dev Biol Anim; 2018 Jun; 54(Suppl 1):2-5. PubMed ID: 29700742
[No Abstract] [Full Text] [Related]
12. Keynote Symposium.
In Vitro Cell Dev Biol Anim; 2018 Jun; 54(Suppl 1):1. PubMed ID: 29700739
[No Abstract] [Full Text] [Related]
13. Development of Toolboxes for Precision Genome/Epigenome Editing and Imaging of Epigenetics.
Nomura W
Chem Rec; 2018 Dec; 18(12):1717-1726. PubMed ID: 30066981
[TBL] [Abstract][Full Text] [Related]
14. Treatments that made headlines in 2018.
Chakradhar S
Nat Med; 2018 Dec; 24(12):1785-1787. PubMed ID: 30523326
[No Abstract] [Full Text] [Related]
15. Clarifying the regulation of genome editing in Australia: situation for food.
Kelly L
Transgenic Res; 2019 Aug; 28(Suppl 2):161-164. PubMed ID: 31321699
[No Abstract] [Full Text] [Related]
16. CRISPR: From Prokaryotic Immune Systems to Plant Genome Editing Tools.
Bandyopadhyay A; Mazumdar S; Yin X; Quick WP
Adv Exp Med Biol; 2017; 1016():101-120. PubMed ID: 29130156
[TBL] [Abstract][Full Text] [Related]
17. National Academies relax stance on germline edits.
Sheridan C
Nat Biotechnol; 2017 Apr; 35(4):295-296. PubMed ID: 28398320
[No Abstract] [Full Text] [Related]
18. How genome editing could be used in the treatment of cardiovascular diseases.
Musunuru K
Per Med; 2018 Mar; 15(2):67-69. PubMed ID: 29714123
[No Abstract] [Full Text] [Related]
19. An overview of OECD activities related to modern techniques of biotechnology and genome editing : OECD conference on genome editing, June 2018.
Kearns P
Transgenic Res; 2019 Aug; 28(Suppl 2):41-44. PubMed ID: 31321681
[No Abstract] [Full Text] [Related]
20. CRISPR gene-editing tested in a person for the first time.
Cyranoski D
Nature; 2016 Nov; 539(7630):479. PubMed ID: 27882996
[No Abstract] [Full Text] [Related]
[Next] [New Search]
